Epysqli

Bio & Pharma Samsung Bioepis leads in Soliris biosimilar market in Europe

STOCKHOLM – Samsung Bioepis Co.'s biosimilar to Soliris for the treatment of patients with rare, life-threatening disease paroxysmal nocturnal...

Bio & Pharma Samsung Bioepis to enhance biosimilar presence with Epysqli

FRANKFURT – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is looking to gain ground in the ra...

Bio & Pharma Samsung Bioepis gets approval to sell biosimilar in Europe

South Korea's Samsung Bioepis has received approval in Europe to sell a biosimilar of Soliris, a drug for the treatment of adult and children patien...